Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C - PubMed (original) (raw)
Comparative Study
. 2011 Oct;60(10):1394-402.
doi: 10.1136/gut.2010.222844. Epub 2011 Jan 26.
Elena Lima-Cabello, Sonia Sánchez-Campos, María Victoria García-Mediavilla, Miguel Fernández-Bermejo, Tamara Lozano-Rodríguez, Javier Vargas-Castrillón, Xabier Buqué, Begoña Ochoa, Patricia Aspichueta, Javier González-Gallego, Carmelo García-Monzón
Affiliations
- PMID: 21270117
- DOI: 10.1136/gut.2010.222844
Comparative Study
Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C
María Eugenia Miquilena-Colina et al. Gut. 2011 Oct.
Abstract
Background: Fatty acid translocase CD36 (FAT/CD36) mediates uptake and intracellular transport of long-chain fatty acids in diverse cell types. While the pathogenic role of FAT/CD36 in hepatic steatosis in rodents is well-defined, little is known about its significance in human liver diseases.
Objective: To examine the expression of FAT/CD36 and its cellular and subcellular distribution within the liver of patients with non-alcoholic fatty liver disease (NAFLD) and chronic hepatitis C virus (HCV) infection.
Patients: 34 patients with non-alcoholic steatosis (NAS), 30 with non-alcoholic steatohepatitis (NASH), 66 with HCV genotype 1 (HCV G1) and 32 with non-diseased liver (NL).
Methods: Real-time PCR and western blot analysis were used to assess hepatic FAT/CD36 expression. Computational image analysis of immunostained liver biopsy sections was performed to determine subcellular distribution and FAT/CD36 expression index.
Results: Compared with NL, hepatic mRNA and protein levels of FAT/CD36 were significantly higher in patients with NAS (median fold increase 0.84 (range 0.15-1.61) and 0.66 (range 0.33-1.06), respectively); NASH (0.91 (0.22-1.81) and 0.81 (0.38-0.92), respectively); HCV G1 without steatosis (0.30 (0.17-1.59) and 0.33 (0.29-0.52), respectively); and HCV G1 with steatosis (0.85 (0.15-1.98) and 0.87 (0.52-1.26), respectively). In contrast to NL, FAT/CD36 was predominantly located at the plasma membrane of hepatocytes in patients with NAFLD and HCV G1 with steatosis. A significant correlation was observed between hepatic FAT/CD36 expression index and plasma insulin levels, insulin resistance (HOMA-IR) and histological grade of steatosis in patients with NASH (r=0.663, r=0.735 and r=0.711, respectively) and those with HCV G1 with steatosis (r=0.723, r=0.769 and r=0.648, respectively).
Conclusions: Hepatic FAT/CD36 upregulation is significantly associated with insulin resistance, hyperinsulinaemia and increased steatosis in patients with NASH and HCV G1 with fatty liver. Translocation of this fatty acid transporter to the plasma membrane of hepatocytes may contribute to liver fat accumulation in patients with NAFLD and HCV.
Similar articles
- Hepatic insulin resistance is associated with increased apoptosis and fibrogenesis in nonalcoholic steatohepatitis and chronic hepatitis C.
García-Monzón C, Lo Iacono O, Mayoral R, González-Rodríguez A, Miquilena-Colina ME, Lozano-Rodríguez T, García-Pozo L, Vargas-Castrillón J, Casado M, Boscá L, Valverde AM, Martín-Sanz P. García-Monzón C, et al. J Hepatol. 2011 Jan;54(1):142-52. doi: 10.1016/j.jhep.2010.06.021. Epub 2010 Aug 27. J Hepatol. 2011. PMID: 20888662 - Non-alcoholic fatty liver disease and hepatitis C infection.
Bondini S, Younossi ZM. Bondini S, et al. Minerva Gastroenterol Dietol. 2006 Jun;52(2):135-43. Minerva Gastroenterol Dietol. 2006. PMID: 16557185 Review. - Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis.
Bugianesi E, Marchesini G, Gentilcore E, Cua IH, Vanni E, Rizzetto M, George J. Bugianesi E, et al. Hepatology. 2006 Dec;44(6):1648-55. doi: 10.1002/hep.21429. Hepatology. 2006. PMID: 17133473 - Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor-alpha in chronic hepatitis C patients.
Durante-Mangoni E, Zampino R, Marrone A, Tripodi MF, Rinaldi L, Restivo L, Cioffi M, Ruggiero G, Adinolfi LE. Durante-Mangoni E, et al. Aliment Pharmacol Ther. 2006 Nov 1;24(9):1349-57. doi: 10.1111/j.1365-2036.2006.03114.x. Aliment Pharmacol Ther. 2006. PMID: 17059516 - Review article: non-alcoholic fatty liver disease and hepatitis C--risk factors and clinical implications.
Sanyal AJ. Sanyal AJ. Aliment Pharmacol Ther. 2005 Nov;22 Suppl 2:48-51. doi: 10.1111/j.1365-2036.2005.02596.x. Aliment Pharmacol Ther. 2005. PMID: 16225473 Review.
Cited by
- Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease.
Kawano Y, Cohen DE. Kawano Y, et al. J Gastroenterol. 2013 Apr;48(4):434-41. doi: 10.1007/s00535-013-0758-5. Epub 2013 Feb 9. J Gastroenterol. 2013. PMID: 23397118 Free PMC article. Review. - Hepatic Overexpression of CD36 Improves Glycogen Homeostasis and Attenuates High-Fat Diet-Induced Hepatic Steatosis and Insulin Resistance.
Garbacz WG, Lu P, Miller TM, Poloyac SM, Eyre NS, Mayrhofer G, Xu M, Ren S, Xie W. Garbacz WG, et al. Mol Cell Biol. 2016 Oct 13;36(21):2715-2727. doi: 10.1128/MCB.00138-16. Print 2016 Nov 1. Mol Cell Biol. 2016. PMID: 27528620 Free PMC article. - Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways.
Badmus OO, Hillhouse SA, Anderson CD, Hinds TD, Stec DE. Badmus OO, et al. Clin Sci (Lond). 2022 Sep 30;136(18):1347-1366. doi: 10.1042/CS20220572. Clin Sci (Lond). 2022. PMID: 36148775 Free PMC article. Review. - Hyperinsulinemia Enhances Hepatic Expression of the Fatty Acid Transporter Cd36 and Provokes Hepatosteatosis and Hepatic Insulin Resistance.
Steneberg P, Sykaras AG, Backlund F, Straseviciene J, Söderström I, Edlund H. Steneberg P, et al. J Biol Chem. 2015 Jul 31;290(31):19034-43. doi: 10.1074/jbc.M115.640292. Epub 2015 Jun 17. J Biol Chem. 2015. PMID: 26085100 Free PMC article. - Low-Dose Administration of Cannabigerol Attenuates Inflammation and Fibrosis Associated with Methionine/Choline Deficient Diet-Induced NASH Model via Modulation of Cannabinoid Receptor.
Aljobaily N, Krutsinger K, Viereckl MJ, Joly R, Menlove B, Cone B, Suppes A, Han Y. Aljobaily N, et al. Nutrients. 2022 Dec 30;15(1):178. doi: 10.3390/nu15010178. Nutrients. 2022. PMID: 36615835 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources